Attovia Therapeutics Inc（ATTO）资讯与事件ATTOAttovia Therapeutics Inc

Attovia Completes IPO and Advances ATTO-1310 Clinical Studies

"Following the successful completion of our upsized IPO, Attovia enters its next exciting phase with a strong balance sheet and clear line of sight to multiple potential near-term value-creating milestones," said Tao Fu, founder and CEO of Attovia. "The preliminary clinical proof of concept for ATTO-1310 in chronic pruritus and high-itch AD provides important validation of both the program and our ATTOBODY platform. We are advancing ATTO-1310 toward two large Phase 2 studies while progressing ATTO-2306 and ATTO-1091 toward the clinic in the first half of 2027. With multiple internally discovered programs moving through development, we remain focused on disciplined execution and building Attovia into a sustainable, multi-product biotechnology company with the goal of shaping the future of immune-mediated diseases."

Several Companies Successfully Debut, BlossomHill Therapeutics Opens at $16.08

Several companies made their market debuts in the past week, highlighted by strong demand for new biopharma listings and a rare secondary only bank offering that drew attention for its structure.LATEST IPOS AND DIRECT LISTINGS:BlossomHill Therapeuticsopened on August 7 at $15.75. The company priced 9.375M shares at $16.00. The deal size was increased to 9.375M shares of common stock from 7.8M shares of common stock and priced within the $15.00-$17.00 range. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer.Latigo Biotherapeuticsopened on August 7 at $21. The clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines priced 19.2M shares at $18.00. The deal size was increased to 19.2M shares of common stock from 16M shares of common stock and priced at the high-end of the $16.00-$18.00 range.Ticketplusopened on August 7 at $7. The company priced 1.875M shares at $8.00. The deal priced at the low end of its $8.00-$10.00 range. Ticketplus is a technology company that operates a proprietary, full-stack technology platform powering live entertainment across Latin America.Braveheart Bioopened on August 6 at $30.20. The clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced above the $15.00-$17.00 range.River City Bankopened on August 6 at $45. The company priced its initial public offering of 2.7M shares of its common stock at a public offering price of $45.00 per share. The offering consists solely of existing shares held by two of the bank's longtime shareholders associated with the family of the bank's founder, Jon Kelly. As a result, the IPO is structured as a 100% secondary offering, with no new shares issued by the bank, River City noted. As of June 30, River City Bank had approximately $6.0B in assets, $4.7B in gross loans, and $5.4B in deposits.Attoviaopened on August 5 at $21.00. The company priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00 range. All shares of common stock to be sold in the offering will be sold by Attovia. Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.RECENT SPAC IPOS:Pinnacle Acquisitionopened on August 7 at $9.97. Santander and CIBC Capital Markets are acting as joint book-running managers.TCGX Acquisitionopened on August 5 at $10.30. While the company may pursue an acquisition opportunity in any business, industry, sector or geographical location, it intends to focus its search on the healthcare and healthcare-related industries, particularly in the life sciences and medical technology sectors.PERFORMANCE:Prices as of 10:45 am ET on Monday, August 10 -BlossomHill Therapeutics – fractionally up at $16.08;Latigo Biotherapeutics – up over 1% at $18.47;Ticketplus – up more than 2% at $7.17;Braveheart Bio – fractionally up at $30.11;River City Bank – fractionally down at $46.76;Attovia – down almost 6% at $19.04;RECENT IPOS TO WATCH:Standard Nuclearand Csquareare already seeing coverage roll out, while QumulusAIis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include EvoAirand Inspire Brands.Clickto see upcoming IPO calendar on TipRanks.EvoAir Holdingshas filed for a firm commitment initial public offering of shares of common stock and anticipates that the initial public offering price of shares will be between $4.00 and $5.00 per share. The company said it will apply to list its common stock on the Nasdaq Capital Market under the symbol "EVOH". EvoAir Group is an emerging green technology focusing on eco-friendly heating, ventilation, air conditioning inventions and efforts in the environmental, social and governance initiatives. The Group is principally engaged in the research and development, manufacturing, sale and marketing of HVAC products for residential, commercial and industrial uses.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.

Attovia Prices 17 Million Shares at $17.00

Attovia priced 17M shares at $17.00. The deal size was increased to 17M shares of common stock from 12.5M shares. The deal priced at the top of the $15.00-$17.00 range. All shares of common stock to be sold in the offering will be sold by Attovia. Attovia's common stock is expected to begin trading on the Nasdaq Global Market under the symbol "ATTO." Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager for the offering. Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.